File(s) under permanent embargo
Target populations for first-in-human embryonic stem cell research in spinal cord injury
journal contribution
posted on 2023-05-17, 06:16 authored by Bretzner, F, Frederic GilbertFrederic Gilbert, Baylis, F, Brownstone, RGeron recently announced that it had begun enrolling patients in the world's first-in-human clinical trial involving cells derived from human embryonic stem cells (hESCs).This trial raises important questions regarding the future of hESC-based therapies, especially in spinal cord injury (SCI) patients. We address some safety and efficacy concerns with this research, as well as the ethics of fair subject selection. We consider other populations that might be better for this research: chronic complete SCI patients for a safety trial, subacute incomplete SCI patients for an efficacy trial, and perhaps primary progressive multiple sclerosis (MS) patients for a combined safety and efficacy trial.
History
Publication title
Cell Stem CellVolume
8Issue
5Pagination
468-475ISSN
1934-5909Department/School
School of HumanitiesPublisher
ElsevierPlace of publication
Cambridge MARights statement
The definitive version is available at http://www.sciencedirect.comRepository Status
- Restricted